2009 MAVRC Pilot Fund Awardees
MAVRC is proud to announce the Awardees of the 2009 MAVRC Pilot Funds for Human Immunobiology Studies. Congratulations to the recipients of the two $25,000 awards for innovative and collaborative research projects to explore mucosal and vaccine biology.
|
Dr. Adit Ginde |
Vitamin D Supplementation and Varicella Zoster Virus Vaccine Responsiveness in Older Nursing Home Residents
PI: Adit A. Ginde, MD, MPH; Assistant Professor of Surgery
Co-I: Myron J. Levin, MD; Professor of Pediatrics
Co-I: Robert S. Schwartz, MD; Professor of Medicine |
|
Dr. David Beckham |
Cytokine Biomarkers in Patients with Central Nervous System Infections
PI: J. David Beckham, MD; Associate Professor of Infectious Diseases
Co-I: Kenneth L. Tyler, MD; Professor of Neurology, Infectious
Diseases, and Microbiology
Co-I: Charles A. Dinarello, MD; Professor of Infectious Diseases |
The Mucosal and Vaccine Research Colorado (MAVRC) program is soliticing applications for pilot award funding for collaborative human immunobiology studies. MAVRC promotes new interactions between a diverse spectrum of researchers to explore mucosal and vaccine biology and disease. Our goal is to foster and facilitate the development of innovative collaborative, interdisciplinary biomedical research programs in human mucosal biology, immunology and vaccine development.
Eligibility
Applicant teams will include basic and clinical faculty investigators, with an emphasis on new interdepartmental or inter-institutional collaborations. Academic researchers must become MAVRC members in order to apply. To access the simple application, click the "Join MAVRC" button on webpage http://medschool.ucdenver.edu/MAVRC. A free membership entitles you to access to pilot funding opportunities, administrative support for new research and funding, shared sponsorship for speakers, and participation in a statewide collaborative research network.
Proposals will represent new and creative projects investigating human immunobiology, supported by a concrete plan for specific subsequent external funding. Submissions will be reviewed by the MAVRC Board of Directors for significance, innovation, approach, and budget. Relevant IRB approval must be attained prior to the award allocation.
Two innovative pilot projects will be selected to receive a $25,000 award for studies to be conducted within a one year period, with no carryover. The awards will cover direct costs only, including supplies, (non Principal Investigator) salaries, patient costs, and should not supplement other grants.
Applications
Applications are due September 15, 2009 in pdf form emailed to MAVRC@ucdenver.edu. A three-page proposal (covering numbers 2-6; Arial 11 font) in NIH format will include:
1. Cover page (Title and Investigators)
2. Hypotheses
3. Specific Objectives
4. Background, including special significance
5. Work proposed
6. Plan for subsequent funding
7. IRB plan for protection of human subjects (approval due prior to funding)
8. Budget (direct costs only; no indirect costs provided) (one page)
9. NIH biosketch of each Investigator
Notification of Awards
Selected awardees will be announced October 15, 2009. Brief summary statements will be provided. Funding commences with IRB approval.